Over the past few seasons, Sam Hauser has been a vital part of the Boston Celtics rotation . Hauser’s size, shooting, and high IQ make him an ideal fit in the Celtics’ system. However, the 6-foot-8 wing is in the midst of a down season, in large part due to a back injury that has kept him sidelined at various points of the season. Let’s dive into Hauser’s comments and how his back injury is impacting his play. Celtics’ Forward Sam Hauser Opens Up About Nagging Injury Before the Celtics’ recent game against the Indiana Pacers , Hauser discussed his back injury and how it’s affected his season so far. Sam Hauser on having to deal with back injuries: “It sucks, obviously, getting hurt — but just trying to do everything I can not to let it happen again. “It’s been a little frustrating... trying to find a rhythm. And that’s tough sometimes, but just working through it.” pic.twitter.com/bPK0ZxAw1z — Noa Dalzell (@NoaDalzell) December 27, 2024 Last season, Hauser averaged 9.0 points and 3.5 rebounds on 44.6 percent shooting from the field and 42.4 percent from beyond the arc. Through 24 games this season, he is averaging 7.7 points and 3.3 rebounds on 42.5 percent shooting from the field and 35.6 percent from beyond the arc. Hauser’s injury is a key reason for his down year. Notably, Hauser has already missed more games than the previous two seasons combined. His dip in three-point shooting has been the most noticeable drop-off. Hauser’s shooting has been a central part of his and the Celtics’ success in recent years. Before this year, Hauser had shot 40 percent or more in each of his three seasons, dropping to a league average 35 percent is certainly concerning. This dip in shooting is paired with the Celtics’ three-point percentage declining from 38.8 to 36.6 while the team is taking eight more threes per game. Additionally, Hauser looks less mobile on both ends of the floor. In the Celtics’ recent game against the Pacers, Hauser earned a starting spot with Kristaps Porzingis and Jrue Holiday sidelined, he scored four points on 2-8 shooting from the field and 0-5 shooting from beyond the arc. Can Hauser Get Back on Track? While Hauser has struggled so far this season, he is still an important part of the Celtics’ rotation, and there’s plenty of time for him to get back on track. Despite his struggles, Hauser is still averaging 21.7 minutes per game compared to 22 minutes last season; this underscores Joe Mazzulla ‘s trust in him. Hauser has missed five games due to his back injury, including recent consecutive games against the Chicago Bulls and three straight games in October. He also missed a game against the Detroit Pistons in December with an abductor injury. Furthermore, he has frequently been a game-time decision at various points this season due to his back injury. To Hauser’s point, it’s challenging to find a rhythm, especially as a spot-up shooter, when you are constantly in and out of the lineup. Back injuries can linger for a while, for Hauser and the Celtics’ sake, let’s hope this injury goes away sooner rather than later. Ultimately, Hauser returning to his 2023-24 season form would greatly benefit the Celtics. This article first appeared on Last Word On Sports and was syndicated with permission.Srinagar, Dec 28 (PTI) Jammu and Kashmir Chief Minister Omar Abdullah visited his Assembly constituency, Ganderbal, on Saturday to take stock of the situation in the aftermath of snowfall, officials said. Abdullah visited his constituency to assess the situation first-hand and monitor the district administration's efforts to provide relief to people, they added. The officials said the chief minister paid an unannounced visit to the district hospital to assess its preparedness in providing healthcare services. He interacted with the hospital staff as well as patients and their attendants, and emphasised the importance of ensuring uninterrupted medical services, the officials said. They said the chief minister also enquired about the heating arrangements at the hospital, and the availability of staff, essential medicines and other facilities. Later, he visited the mini-secretariat complex and took stock of the situation across the Union Territory from the deputy commissioner's office at Ganderbal, the officials said. They said Abdullah chaired a crucial meeting with divisional commissioners of Jammu and Kashmir and all deputy commissioners to review the snow-clearance and power and water supply scenarios. He directed the officers to take swift action to ensure uninterrupted essential services after the snowfall, the officials said. Talking to reporters in Ganderbal, Abdullah said he visited Ganderbal to ensure that people do not face much hardships due to the snow. "I wanted to ensure that the snow-clearance operations on roads were sped up and electricity was restored wherever the lines were snapped. I also wanted to take stock of hospital and essential services," he said. The chief minister said he is monitoring the situation in other districts of the valley as well. "There are places where electricity has been affected due to snowfall and that would be restored by Saturday evening. Efforts are also on to clear the roads that are blocked due to snow," he said. Asked about the restoration of water supply in certain areas, the chief minister said wherever the supply can be restored immediately, it would be done, and wherever it would take time, water tankers would be made available. (This story has not been edited by THE WEEK and is auto-generated from PTI)Here’s what to know about funding deal that countries agreed to at UN climate talks
Fans Are ‘Heartbroken’ After Longtime ‘General Hospital’ Cast Member Announces Surprising DepartureHeavy travel day off to a rough start after American Airlines briefly grounds all flights
TEL AVIV, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI. Teva recently communicated that it was open to exploring new strategic approaches in Japan, including a possible divestment of its Teva-Takeda business venture, in alignment with its Pivot to Growth strategy. The divestment will allow Teva to focus on its innovative medicines business in Japan. Teva expects the divestiture to be completed by 1 April, 2025, subject to standard closing conditions, including obtaining required regulatory approvals. All the employees of the business venture in Japan will remain employed, subject to the terms of the agreement. “This is another step in our Pivot to Growth strategy to focus the business,” said Mark Sabag, Executive Vice President, International Markets Commercial. “Furthermore, we are confident that this agreement with JKI will ensure the continued delivery of high-quality, affordable medicines to patients in Japan.” About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com . Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks and uncertainties relating to: our ability to successfully divest our Teva-Takeda business venture in Japan; the terms, timing, structure, benefits and costs of such divestiture and whether such divestiture will be consummated at all; the impact of any divestiture transaction on the remaining businesses of Teva in Japan and our ability to focus on our innovative business in Japan; our ability to satisfy the closing conditions to completing the divestiture of our business venture in Japan, including to obtain the required regulatory approvals; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2024 and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.Dow ends at fresh record as weak eurozone data hits euroThese were the most disappointing TV shows of the year
Growing to 4.2M people in Metro Vancouver 'a bit too much' without a plan: Mike Hurley
Oscar-winning director Christopher Nolan will be taking audiences to mythical Greece with his latest project. Universal Pictures announced this week that Nolan will be directing a cinematic adaptation of “ The Odyssey ,” an ancient poem believed to be written by Homer between 750 and 650 BCE centering on the character Odysseus’ 10-year trek home after the Trojan War. Nolan’s forthcoming adaptation is described as “a mythic action epic shot across the world using brand new IMAX film technology,” according to the studio’s announcement posted to their X page Monday. Zendaya, Tom Holland and Robert Pattinson along with Oscar-winners Matt Damon, Lupita Nyong’o, Anne Hathaway and Charlize Theron are reportedly set to star in the film. Holland recently spoke about signing onto the project, saying on “The Dish” podcast last week that the film hasn’t started shooting yet. He added that Nolan only “loosely pitched” it to him when they met to discuss the project, but that he still didn’t know all the details. The “Spider-Man” actor also touched on working with his girlfriend Zendaya, joking that “studios love it” when they’re on the same project because they only have to pay for “one hotel room.” Pattinson, Damon and Hathaway have all previously appeared in Nolan’s films, including “Tenet,” “Interstellar” and “Oppenheimer.” Nolan is also behind epic films including “Inception,” “The Dark Knight,” “Dunkirk” and his most recent film “Oppenheimer,” which scored big at last year’s Oscars when it took home the trophy for best picture. Nolan won that award as a producer, and also took home the Academy Award for best director. According to Universal’s social media announcement this week, “The Odyssey” will bring Homer’s “foundational saga to IMAX film screens for the first time” and will open in theaters on July 17, 2026.
L.A. Times Planning to Add AI-Powered ‘Bias Meter’ to Every StoryNone
Elon Musk’s preschool is the next step in his anti-woke education dreams